SEC Form 4 · accession 0001140361-15-042301
NEVRO CORP · NVRO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Andrew H Galligan
Officer — Chief Financial Officer
Period of report
Nov 17, 2015
Accepted (ET)
Nov 19, 2015 · 4:08 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001444380
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 17, 2015 | M | 10,446 | $1.44 | A | 10,446 | D | |
| Common Stock | Nov 17, 2015 | M | 869 | $3.60 | A | 11,315 | D | |
| Common Stock | Nov 17, 2015 | M | 4,070 | $3.60 | A | 15,385 | D | |
| Common Stock | Nov 17, 2015 | M | 4,615 | $18.00 | A | 20,000 | D | |
| Common StockF2 | Nov 17, 2015 | S | 18,500 | $51.2366 | D | 1,500 | D | |
| Common StockF3 | Nov 17, 2015 | S | 1,500 | $52.008 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F4 | $1.44 | Nov 17, 2015 | M | 10,446 | D | — | May 17, 2020 | Common Stock | 10,446 | 77,404 | D |
| Stock Option (right to buy)F4 | $3.60 | Nov 17, 2015 | M | 869 | D | — | Sep 28, 2021 | Common Stock | 869 | 62,940 | D |
| Stock Option (right to buy)F5 | $3.60 | Nov 17, 2015 | M | 4,070 | D | — | May 14, 2023 | Common Stock | 4,070 | 44,804 | D |
| Stock Option (right to buy)F6 | $18.00 | Nov 17, 2015 | M | 4,615 | D | — | Nov 4, 2024 | Common Stock | 4,615 | 51,899 | D |
Explanation of responses
- F1The sales were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
- F2The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $51.00 to $51.9876, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F3The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $52.00 to $52.03, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F4100% of the shares subject to the option are fully vested and exercisable.
- F51/48th of the shares subject to the option vest on each monthly anniversary measured from May 15, 2013 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
- F61/48th of the shares subject to the option vest on each monthly anniversary measured from November 5, 2014 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.